Showing 3181-3190 of 7410 results for "".
- Vial Welcomes David Pariser, MD to its Boardhttps://practicaldermatology.com/news/vial-welcomes-david-pariser-md-to-its-board/2461105/David Pariser, MD has joined the Vial Scientific Advisory Board. The Senior Physician at Pariser Dermatology Specialists, Dr. Pariser will share the Vial CRO team and sponsors his knowledge and insights from more than 40 years as a practicing dermatologist. The
- Dermatologists Can Support Medical, Humanitarian Efforts in Ukrainehttps://practicaldermatology.com/news/how-to-help-ukraine/2461103/Many Americans feel hopeless as they watch images of displaced Ukrainian citizens fleeing their country due to ongoing Russian attacks. EADV President Professor Alexander Stratigos and Secretary General Professor Carmen Salavastru have issued a sta
- Study: Use of DermTech’s Melanoma Test Can Cut Costshttps://practicaldermatology.com/news/study-use-of-dermtechs-melanoma-test-can-cut-costs/2461102/New research shows that DermTech’s Pigmented Lesion Assay can reduce costs for commercial health insurance plans when it’s incorporated into the current care pathway of assessing pigmented skin lesions or moles suspicious for melanoma The
- Study: Melanoma Referral Centers Worldwide Adopt Systemic Therapies, Reduce Lymph Node Removal Surgerieshttps://practicaldermatology.com/news/study-melanoma-referral-centers-worldwide-adopt-systemic-therapies-reduce-lymph-node-removal-surgeries/2461097/Lymph node removal surgery for patients with high-risk melanoma has become less common over the past few years while the use of targeted and immune therapies has risen rapidly at melanoma referral centers worldwide, an international group of researchers found. However, a large degree of
- Mblue Labs Introduces First Anti-Aging, Coral Safe Sunscreen with Methylene Bluehttps://practicaldermatology.com/news/mblue-labs-introduces-first-anti-aging-coral-safe-sunscreen-with-methylene-blue/2461094/Mblue Labs is launching Bluevado SunFix, the first sunscreen with Methylene Blue, a centuryold medicine that is also safe for coral reefs and also delays skin aging. Fully 80 percent of today’s sunscreens use Oxybenzone as a chemical UV blocker, despite studies that have show
- Cetaphil Sensitive Skin Awareness Month Kicks off on March 1, 2022https://practicaldermatology.com/news/cetaphil-sensitive-skin-awareness-month-kicks-off-on-march-1-2022/2461093/Cetaphil is extending Sensitive Skin Awareness Week to a month-long program. Cetaphil is debuting Sensitive Skin Awareness Month this March. In partnership with expert dermatologists and influencers – dubbed the Sensitive Skin Academy – Cetaphil 
- Vial Names Dr. Mark Lebwohl to Scientific Advisory Boardhttps://practicaldermatology.com/news/vial-names-dr-mark-lebwohl-to-scientific-advisory-board/2461091/The Vial Dermatology CRO has added Mark Lebwohl, MD, MPH to the Vial Scientific Advisory Board. Dr. Lebwohl will lend his expertise to the Vial CRO team and leading sponsors working to advance the Dermatology research field.<
- Study: More Than Half of Postmenopausal Women Experience Female Pattern Hair Losshttps://practicaldermatology.com/news/study-more-than-half-of-postmenopausal-women-experience-female-pattern-hair-loss/2461079/More than half of postmenopausal women experience female pattern hair loss, according to a studypublished online in Menopause. In a new cross-sectional study involving 178 women seen at a menopause clinic, researchers aimed to evaluate the prevalence of female pat
- Study: Oral Dutasteride Outperforms Other Male Hair Loss Treatmentshttps://practicaldermatology.com/news/study-oral-dutasteride-outperforms-other-male-hair-loss-treatments/2461073/The top-ranking hair loss treatment for men is dutasteride (Avodart) capsules, at a dose of 0.5 milligrams a day, according to a new meta-analysis of 23 studies published online Feb. 2 in
- Solta Medical Files for IPOhttps://practicaldermatology.com/news/solta-medical-files-for-ipo/2461072/Bausch Subsidiary Solta Medical Corporation is getting ready to go public. The Company publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering ("IPO") of Solta's common shares.